Welcome to our dedicated page for Syndax Pharmaceuticals news (Ticker: SNDX), a resource for investors and traders seeking the latest updates and insights on Syndax Pharmaceuticals stock.
Syndax Pharmaceuticals, Inc. (symbol: SNDX) is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts. Dedicated to the development of combination therapies, the company primarily focuses on innovative treatments for various cancer indications.
Syndax's pipeline is rich with promising drugs aimed at improving the lives of cancer patients. The company's leading candidates include entinostat, an agent that targets both cancer cells and immune regulatory cells, and revumenib, a selective inhibitor of the menin-KMT2A binding interaction. This agent is particularly geared towards addressing acute leukemias such as KMT2A-rearranged (KMT2Ar) and NPM1-mutant acute myeloid leukemia (AML). Another notable product in development is axatilimab, a monoclonal antibody designed to enhance the immune response against tumors through CSF-1R inhibition.
Syndax operates primarily within the United States and has achieved several milestones. Recently, the company completed enrollment in the pivotal AUGMENT-101 trial for revumenib targeting relapsed/refractory mutant nucleophosmin (mNPM1) AML. The trial aims to evaluate revumenib's safety, tolerability, and efficacy, with topline data expected by the end of 2024. Positive results from this trial could support new drug applications in early 2025.
Revumenib has achieved several regulatory designations, including Orphan Drug, Fast Track, and Breakthrough Therapy by the FDA, reflecting its potential to address unmet clinical needs in leukemias. Syndax has also reported encouraging outcomes from its studies, including high response rates and favorable safety profiles in both adult and pediatric populations suffering from acute leukemia.
Financially, Syndax maintains a robust position to advance its clinical programs. The company regularly updates stakeholders through earnings calls and investor presentations, with a recent update scheduled for May 2024. Syndax's progress is further bolstered by strategic partnerships and collaborations that support its mission to innovate and deliver significant value to patients and shareholders alike.
Syndax Pharmaceuticals (SNDX) will release its Q3 2022 financial results on November 3 after market close. Management will host a conference call and live audio webcast at 4:30 p.m. ET on the same day to discuss the results and company updates. The Q3 earnings call will be accessible through the company's website. Syndax is focused on innovative cancer therapies, with key assets like revumenib and axatilimab in pivotal trials. Further information can be found on their website.
Syndax Pharmaceuticals (SNDX) reported its Q2 2022 financial results, revealing a net loss of $37.6 million, or $0.62 per share, compared to a loss of $22.9 million, or $0.44 per share, in the previous year. The company has $378.9 million in cash and equivalents as of June 30, 2022. Key developments include the ongoing pivotal trials for revumenib and axatilimab, with topline data expected in the first half of 2023. R&D expenses surged to $29.7 million, attributed to clinical activities for both compounds.
Syndax Pharmaceuticals, a clinical-stage biopharmaceutical company, will report its second quarter 2022 financial results on August 8, after U.S. market close. A subsequent conference call is scheduled for 4:30 p.m. ET to discuss the results and provide updates. The live audio webcast will be accessible on Syndax's website. Key pipeline highlights include revumenib (SNDX-5613) and axatilimab, both in pivotal trials. Replays will be available post-call for 90 days.
Syndax Pharmaceuticals announced the hiring of Chief Financial Officer Keith A. Goldan, who received an inducement award to purchase 230,000 shares at an exercise price of $15.60. This stock option will vest over four years, with 25% vesting after the first year and the remainder vesting monthly. The award was approved in compliance with NASDAQ Listing Rule 5635(c)(4). Syndax is focused on developing innovative cancer therapies, including revumenib and axatilimab, which are currently in pivotal trials.
Syndax Pharmaceuticals, a clinical-stage biopharmaceutical company, announced the appointment of Keith A. Goldan as Chief Financial Officer. Goldan, with nearly 30 years of experience in the pharmaceutical sector, previously served as CFO at Optinose, assisting in the launch of XHANCE. CEO Michael A. Metzger emphasized Goldan's expertise as crucial for the company's growth. The press release also highlighted upcoming pivotal readouts for revumenib and axatilimab, both targeting significant cancer treatment needs. Additionally, Sharon Klahre was appointed Vice President of Investor Relations.
Syndax Pharmaceuticals, a clinical-stage biopharmaceutical company, has announced participation in two investor conferences. Management will engage in a virtual fireside chat at Cowen's 3rd Annual Oncology Innovation Summit on June 2, 2022, at 12:30 p.m. ET. Additionally, they will partake in a fireside chat at Goldman Sachs' 43rd Annual Global Healthcare Conference on June 14, 2022, at 6:20 p.m. ET in Rancho Palos Verdes, CA. Live webcasts of both events will be accessible on their website, along with a limited-time replay.
Syndax Pharmaceuticals, a clinical-stage biopharmaceutical firm focused on cancer therapies, announced CEO Michael A. Metzger's participation in a targeted oncology panel at Citi's Biopharma Virtual Co-Panel Day on May 18, 2022, at 1:30 p.m. ET. The event will highlight the company's innovative drug pipeline, including revumenib and axatilimab, which are currently in pivotal trials. A live webcast of the panel will be available on their website, along with a replay for limited access.
Syndax Pharmaceuticals (SNDX) reported its Q1 2022 financial results, revealing a net loss of $37.2 million or $0.63 per share, up from a loss of $27.7 million or $0.54 per share in Q1 2021. Research and development expenses rose to $30 million from $21.9 million due to increased clinical activities. The company is advancing its pivotal trials for revumenib (SNDX-5613) and axatilimab, with topline data expected in 1H23 and two FDA filings planned for 2023. As of March 31, 2022, Syndax had $397.9 million in cash and equivalents.
Syndax Pharmaceuticals (SNDX) will release its first quarter 2022 financial results on May 9, 2022, after U.S. market close. A conference call and audio webcast will follow at 4:30 p.m. ET to discuss the results and business updates. Interested parties can access the webcast on the company's website. Syndax's pipeline includes promising cancer therapies such as SNDX-5613, a Menin–MLL inhibitor, axatilimab, a CSF-1 receptor blocker, and entinostat, a class I HDAC inhibitor.
Syndax Pharmaceuticals announced an inducement award for its new Chief Medical Officer, Dr. Catherine Madigan, granting her the option to purchase 180,000 shares of common stock at an exercise price of $16.06, equal to the closing stock price on March 1, 2022. This option will vest over four years, with a quarter vesting after one year and the remainder vesting monthly after that. The award, approved by Syndax's Board of Directors, complies with NASDAQ Listing Rule 5635(c)(4). Syndax is developing a pipeline of innovative cancer therapies including SNDX-5613 and axatilimab.
FAQ
What is the current stock price of Syndax Pharmaceuticals (SNDX)?
What is the market cap of Syndax Pharmaceuticals (SNDX)?
What does Syndax Pharmaceuticals, Inc. specialize in?
What are Syndax's key product candidates?
Where is Syndax Pharmaceuticals located?
What recent milestones has Syndax Pharmaceuticals achieved?
What is the significance of revumenib?
Has revumenib received any special designations?
How does Syndax Pharmaceuticals maintain its financial health?
What upcoming events is Syndax participating in?
Where can I find more information about Syndax's clinical trials?
How can I contact Syndax Pharmaceuticals?
